$ANIK (Anika Therapeutics Inc)

$ANIK {{ '2016-04-04T13:21:24+0000' | timeago}} • Announcement

Specialist in hyaluronic acid technology $ANIK said that it named Stephen Mascioli as the Chief Medical Officer (CMO) and Dana Alexander as the COO. Mr. Mascioli and Ms. Alexander will report to the company's President & CEO, Charles Sherwood. $ANIK also expanded its commercial team by hiring Ms. Jean A. Bjerke as Vice President of Marketing.

$ANIK {{ '2017-07-24T22:09:19+0000' | timeago}} • Announcement

$ANIK said regulatory authorities in India granted approval to MONOVISC, its single injection viscosupplement for the treatment of pain associated with osteoarthritis of all human synovial joints. $ANIK plans to expand MONOVISC into India, Australia, New Zealand and other international markets over the next 6-9 months.

$ABT {{ '2017-07-20T19:55:45+0000' | timeago}} • Webcast

For 3Q17, $ABT expects adjusted EPS of $0.64-0.66, with operational sales growth expected in the mid-single digits. At current exchange rates, the company expects operational sales growth to have a negative YoY impact of around 0.5%.

$ABT {{ '2017-07-20T19:45:56+0000' | timeago}} • Webcast

$ABT said that on a comparable operational basis, 3Q17 Established Pharmaceuticals sales growth is expected in the high double-digit, while in Nutrition, sales growth is expected in low single-digit. In Diagnostics, $ABT expects sales to increase mid-to-high single digits and in Medical Devices, sales is expected to increase double-digits.

$ABT {{ '2017-07-20T17:49:19+0000' | timeago}} • Announcement

$ABT raised its full year profit forecast backed by the intention of closing the Alere acquisition in 2017. The company raised its FY17 adjusted earnings from continuing operations guidance by $0.03 to a range of $2.43-2.53 per share. Reported EPS forecast was also raised from the range of $0.92-1.02 to $1.03-1.13, reflecting double-digit growth.

$ABT {{ '2017-07-20T17:36:53+0000' | timeago}} • Announcement

Declining operating earnings and rising costs and expenses hit $ABT 2Q17 earnings as much as 54%. Earnings plunged to $283MM or $0.15 from $615MM or $0.40 per share a year earlier. Sales, however, surged 24.4% on St. Jude Medical acquisition. On an adjusted basis, $ABT reported EPS above its previous guidance range at $0.62 per share.

$ABT {{ '2017-07-20T12:52:57+0000' | timeago}} • Infographic

$ABT Abbott Laboratories Earnings AlphaGraphic: Q2 2017 Highlights

$GS {{ '2017-07-19T11:22:37+0000' | timeago}} • Webcast

$GS advised a number of important transactions that were announced during 2Q17, including $BCR's $24Bil sale to $BDX. $AMZN's $13.7Bil acquisition of $WFM, and $DFT's $7.6Bil merger with $DLR.

$ANIK {{ '2017-07-17T22:07:56+0000' | timeago}} • Announcement

$ANIK announced preliminary revenue for 2Q17. The company expects total revenue growth to be 23-26% YoY, including licensing, milestone and contract revenue of approx. $5MM as a result of the milestone payment associated with MONOVISC.

$ANIK {{ '2017-07-17T22:07:36+0000' | timeago}} • Announcement

$ANIK will receive a $5MM milestone payment under the terms of its license agreement with its US commercial partner. The milestone payment was triggered by MONOVISC achieving $100MM in US end-user sales within a consecutive 12-month period at the end of June 2017. The company will recognize this milestone payment as revenue in 2Q17.

$ABT {{ '2017-07-17T12:36:21+0000' | timeago}} • Announcement

$ABT is commencing a tender offer to purchase for cash all outstanding shares of Series B Convertible Perpetual Preferred Stock of Alere Inc. at a price of $402 per share of Preferred Stock. The offer will expire at 11:59 pm, NYC time, on Aug 11, 2017. There is no financing condition to the offer.

$ABT {{ '2017-07-13T12:23:21+0000' | timeago}} • Announcement

$ABT and Bigfoot Biomedical agreed to develop and commercialize diabetes management systems, integrating $ABT's FreeStyle Libre glucose sensing technology with Bigfoot's insulin delivery solutions in the United States. $ABT will provide Bigfoot with the next generation of its FreeStyle Libre glucose sensing technology.

$MMM {{ '2017-06-30T15:31:24+0000' | timeago}} • Announcement

$MMM completed the sale of its tolling and automated license/number plate recognition business to Neology, which is a subsidiary of SMARTRAC, a portfolio company managed by One Equity Partners. The impact of the transaction will be neutral to both 2Q17 and full-year 2017 GAAP EPS.

$ABT {{ '2017-06-29T17:53:11+0000' | timeago}} • Announcement

$ABT announced the Health Canada license of its FreeStyle Libre Flash Glucose Monitoring System, a glucose sensing technology for adults with diabetes. This system eliminates the need for routine finger sticks or finger stick calibration, and reads glucose levels through a sensor that can be worn on the back of the upper arm for up to 14 days.

$CMD {{ '2017-06-29T15:44:58+0000' | timeago}} • Announcement

$CMD's BoD authorized a regular semiannual cash dividend of $0.07 per outstanding share of its common stock. The dividend is payable on July 31, 2017 to shareholders of record at the close of business on July 17, 2017.

$HAE {{ '2017-06-23T10:51:04+0000' | timeago}} • Announcement

$HAE announced the formation of a Scientific Advisory Council as part of its broader innovation agenda, advancing its commitment to science and clinical excellence. The SAC will also, as appropriate, provide opinion on strategic issues impacting product and clinical matters.

$ZTS {{ '2017-06-16T17:01:44+0000' | timeago}} • Announcement

Nexvet Biopharma, $ZTS, and Zoetis Belgium jointly dispatched a letter to the holders of convertible securities of Nexvet in accordance with Rule 15 of the Irish Takeover Rules to provide information regarding how the Acquisition of Nexvet by $ZTS will affect such securities.

$ABT {{ '2017-06-16T10:42:39+0000' | timeago}} • Announcement

$ABT announced that the Sekisui CP3000 coagulation system, a fully automated analyzer that tests bleeding and clotting function in blood, is now available in Europe, the Middle East, and Asia Pacific.

$BCR {{ '2017-06-14T21:19:50+0000' | timeago}} • Announcement

$BCR declared a regular quarterly dividend of $0.26 per share. The current indicated annual dividend rate is $1.04 per share. The dividend is payable on August 4, 2017 to shareholders of record at the close of business on July 24, 2017.

$BDX {{ '2017-06-12T07:19:32+0000' | timeago}} • Announcement

$BDX and $BCR received a request for additional information from the Federal Trade Commission in connection with BD's pending acquisition of C.R. Bard. In April 2017, BD agreed to buy Bard in a $24Bil transaction. Both companies expect to get regulatory approvals and close the transaction in the fall of 2017.

$ABT {{ '2017-06-09T14:38:24+0000' | timeago}} • Announcement

The Board of $ABT declared a quarterly common dividend of 26.5 cents per share. The dividend is payable Aug. 15, 2017, to shareholders of record as on July 14, 2017.

Recent Transcripts

ABT (Abbott Laboratories)
Thursday, July 20 2017 - 1:00pm
CMD (Cantel Medical Corp.)
Thursday, June 8 2017 - 3:00pm
ADK (AdCare Health Systems, Inc.)
Tuesday, May 16 2017 - 1:00pm
TEAR (TearLab Corporation)
Monday, May 15 2017 - 8:30pm
HAE (Haemonetics Corporation)
Monday, May 8 2017 - 12:00pm
SYN (Synthetic Biologics Inc.)
Thursday, May 4 2017 - 8:30pm
ANIK (Anika Therapeutics Inc)
Thursday, May 4 2017 - 1:00pm
ZTS (Zoetis Inc.)
Thursday, May 4 2017 - 12:30pm
GMED (Globus Medical, Inc.)
Wednesday, May 3 2017 - 9:30pm
IRIX (IRIDEX Corporation)
Wednesday, May 3 2017 - 9:30pm
STAA (STAAR Surgical Company)
Wednesday, May 3 2017 - 8:30pm
RMD (ResMed Inc.)
Thursday, April 27 2017 - 8:30pm
TNDM (Tandem Diabetes Care, Inc.)
Thursday, April 27 2017 - 8:30pm
MMM (3M Company)
Tuesday, April 25 2017 - 1:00pm
ABT (Abbott Laboratories)
Wednesday, April 19 2017 - 1:00pm
ADK (AdCare Health Systems, Inc.)
Friday, March 24 2017 - 1:00pm
TEAR (TearLab Corporation)
Thursday, March 9 2017 - 9:30pm
CMD (Cantel Medical Corp.)
Thursday, March 9 2017 - 4:00pm
IRIX (IRIDEX Corporation)
Wednesday, March 8 2017 - 10:00pm
TNDM (Tandem Diabetes Care, Inc.)
Wednesday, March 8 2017 - 9:30pm

AlphaGraphics you may like